Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

455 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Testing of new agents in childhood cancer preclinical models: meeting summary.
Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, Helman L, Hirschfeld S, Hollingshead MG, Israel MA, Lock RB, Maris JM, Merlino G, Patterson W, Reynolds CP, Shannon K, Yu A, Yu J, Smith MA. Houghton PJ, et al. Among authors: maris jm. Clin Cancer Res. 2002 Dec;8(12):3646-57. Clin Cancer Res. 2002. PMID: 12473573
Congenital neuroblastoma arising in the deltoid muscle.
Kang T, Dormans J, Maris J, Carpentieri D, Pawel BR, Adamson PC. Kang T, et al. J Pediatr Hematol Oncol. 2004 Feb;26(2):101-3. doi: 10.1097/00043426-200402000-00006. J Pediatr Hematol Oncol. 2004. PMID: 14767196
Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B, Twomey E, Horn B, Reynolds CP, Groshen S, Seeger RC, Maris JM. Matthay KK, et al. Among authors: maris jm. J Clin Oncol. 2006 Jan 20;24(3):500-6. doi: 10.1200/JCO.2005.03.6400. J Clin Oncol. 2006. PMID: 16421427 Clinical Trial.
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.
Fox E, Maris JM, Widemann BC, Meek K, Goodwin A, Goodspeed W, Kromplewski M, Fouts ME, Medina D, Cho SY, Cohn SL, Krivoshik A, Hagey AE, Adamson PC, Balis FM. Fox E, et al. Among authors: maris jm. Clin Cancer Res. 2006 Aug 15;12(16):4882-7. doi: 10.1158/1078-0432.CCR-06-0534. Clin Cancer Res. 2006. PMID: 16914576 Clinical Trial.
The pediatric preclinical testing program: description of models and early testing results.
Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, Reynolds CP, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Zeidner J, Wu J, Liu T, Billups CA, Khan J, Ansher S, Zhang J, Smith MA. Houghton PJ, et al. Among authors: maris jm. Pediatr Blood Cancer. 2007 Dec;49(7):928-40. doi: 10.1002/pbc.21078. Pediatr Blood Cancer. 2007. PMID: 17066459
455 results